Clinical Trial Search

Primary: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum — 4.62; 4.03; -2.24; 5.60 Percentage change in BMD

Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL

Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001

Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03

Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2

Primary: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.059; 0.028 grams per square centimeters — p=<0.001

Primary: Changes in Bone Mineral Density (BMD) — -0.05; -1.45 percentage of change in BMD — p=<0.05

Primary: Number Adherent With the Intervention — 29 participants

Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)

Primary: Change From Baseline (100%) in Ratio of Bone Formation Marker to Bone Resorption Marker — 106.1; 103.6; 112.3; 113.0 percentage change from baseline

Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…

Primary: Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP) — 58.34; 57.91 mcg/L — p=0.05

Primary: Change in Spine Bone Density From Baseline to 2 Years — 8.3; 9.5; 12.9 percent change

Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives

Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change

Primary: Changes in BMD at Femoral Neck — -3.2; 0.25 percentage of change in BMD — p=<0.05

Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2

Primary: Percentage of Change in Trabecular Surface-to-curve Ratio — 9.1; 7.1 Percentage of Change

Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…

Primary: Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms. — -1.28; -1.22 percentage change in BMD — p=<0.05

Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change

Primary: Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). — 11 participants

Primary: Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group. — 2098.7; 1993.3; 2001; 2105.89 mg^2/mm^4 — p=0.7

Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 — 6.5; -.6 Percent Change from Baseline — p=<0.0001

Primary: Percentage Change in Total Hip Bone Mineral Density — 0.60; -6.44 percentage of change

Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants

Primary: Serum Markers of Skeletal Turnover (Serum CTX) — 0.9887; 0.5445 ng/mL

Primary: Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD) — 2.66 Percentage of the baseline value — p=0.01

Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2

Primary: Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) — 0.90; 0.87 g/cm^2 — p=0.009